Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publicado em
- 10 set 2022
- Citações
- 6
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, Neil Martinson, Wadzanai Samaneka, Lerato Mohapi, Sharlaa Badal-Faesen, Rod Dawson, John L Johnson, Harriet Mayanja et al.
Descritores MeSH
- HIV-1
- HIV Infections
- Anti-HIV Agents
- Tuberculosis
- Humans
- Rifampin
- Moxifloxacin
- Benzoxazines
- Alkynes
- Antitubercular Agents
Veja também
Estudos relacionados
- Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
- Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
- Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV